Titan Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Titan Pharmaceuticals generated cash of -$7,092,000, which is more than the previous year. Cash used in financing activities reached the amount of $10,000,000 last year. Net change in cash is therefore $3,640,000.
Cash Flow
| 2014 | -5.86M | -18K | 9.55M |
|---|---|---|---|
| 2015 | -7.46M | -133K | -14K |
| 2016 | 6.29M | -171K | 27K |
| 2017 | -13.03M | -175K | 6.72M |
| 2018 | -8.43M | -416K | 10.62M |
| 2019 | -15.44M | -256K | 11.26M |
| 2020 | -17.20M | -540K | 17.93M |
| 2021 | -7.89M | -23K | 8.84M |
| 2022 | -8.18M | 0 | 4.98M |
| 2023 | -7.09M | 732K | 10M |
TTNP Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 3.13M | 6.33M | 5.41M | 5.22M | 9.65M | 7.88M | 14.00M | 7.85M | 15.47M | 11.79M |
Operating activities | ||||||||||
Net income | -5.56M | -10.20M | -8.77M | -18.24M | -16.45M | -9.02M | -14.30M | 5.13M | -11.27M | -2.40M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 112K | 196K | 221K | 292K | 244K | 380K | 417K | 377K | 358K | 353K |
Stock-based compensation expense | 1.01M | 997K | 1.50M | 7K | 572K | 0 | 1.68M | 1.03M | 1.02M | 543K |
| Deferred income tax benefit | 1.01M | 997K | 1.50M | 7K | 572K | 0 | 1.68M | 1.03M | 1.02M | 543K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -10K | 76K | 642K | 186K | 744K | -1.67M | 3.52M | -245K | -245K | -172K |
Inventories | 0 | 187K | 35K | 287K | 264K | 31K | 0 | 0 | 83K | -808K |
Accounts payable | -476K | -751K | -1.19M | 1.10M | -125K | 542K | -2.19M | -1.14M | -250K | 1.35M |
Cash generated by operating activities | -7.09M | -8.18M | -7.89M | -17.20M | -15.44M | -8.43M | -13.03M | 6.29M | -7.46M | -5.86M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2K | 0 | -23K | -540K | -256K | -416K | -175K | -171K | -133K | -18K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 732K | 0 | -23K | -540K | -256K | -416K | -175K | -171K | -133K | -18K |
Financing activities | ||||||||||
Common Stock Issued | 9.5M | 4.98M | 8.84M | 11.63M | 9.66M | 9.65M | 0 | 0 | -14K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 285K | 0 | 0 | -14K | 0 |
Repayments of term debt | 500K | 0 | 0 | -1.6M | 0 | -3M | 6.72M | 0 | 0 | 0 |
Cash used in financing activities | 10M | 4.98M | 8.84M | 17.93M | 11.26M | 10.62M | 6.72M | 27K | -14K | 9.55M |
Net Change In Cash | 3.64M | -3.19M | 919K | 190K | -4.43M | 1.77M | -6.48M | 6.14M | -7.61M | 3.67M |
Cash at end of period | 6.77M | 3.13M | 6.33M | 5.41M | 5.22M | 9.65M | 7.52M | 14.00M | 7.85M | 15.47M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |